Status:
UNKNOWN
A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin
Lead Sponsor:
Ruijin Hospital
Conditions:
Lymphoma
Eligibility:
All Genders
18-80 years
Brief Summary
This study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. The treatment response and other adverse events will also be studied.
Eligibility Criteria
Inclusion
- histologically confirmed lymphoma
- 18-80 years
- ECOG\<= 2
- newly diagnosed lymphoma
- liposomal doxorubicin is planned in the treatment
- normal lung function
- no history or malignancy
- informed consented
Exclusion
- history of malignancy, now in the treatment
- pregnant
- serious infection
- other uncontrollable conditions judged by the investigator
Key Trial Info
Start Date :
August 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2021
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04069845
Start Date
August 1 2019
End Date
August 30 2021
Last Update
March 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200025